CSF-1/CSF-1R targeting agents in clinical development for cancer therapy

Current Opinion in Pharmacology

Volumn 23, Issue , 2015, Pages 45-51

  Ries, Carola H ^a   Hoves, Sabine ^a   Cannarile, Michael A ^a   Rüttinger, Dominik ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 820; ARRY 382; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; EMACTUZUMAB; ERIBULIN; FPA 008; GEMCITABINE; GW 2580; IMC CS 4; JNJ 40346527; MCS 110; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PACLITAXEL; PLX 3397; PLX 7486; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR RECEPTOR;

ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; GIANT CELL TUMOR; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; MACROPHAGE ACTIVATION; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; MONOCYTE; NONHUMAN; PANCREAS CARCINOMA; PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; NEOPLASMS; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; NEOPLASMS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION;

EID: 84930659709     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.05.008     Document Type: Review

References (55)

1. S.K. Biswas, and A. Mantovani Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat Immunol 11 2010 889 896
2. Q. Zhang, L. Liu, C. Gong, H. Shi, Y. Zeng, X. Wang, Y. Zhao, and Y. Wei Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature PLoS One 7 2012 e50946
3. V. Chitu, and E.R. Stanley Colony-stimulating factor-1 in immunity and inflammation Curr Opin Immunol 18 2006 39 48
4. G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, E. Erba, S. Uboldi, M. Zucchetti, and F. Pasqualini Role of macrophage targeting in the antitumor activity of Trabectedin Cancer Cell 23 2013 249 262
5. G.L. Beatty, E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, W. Sun, R.D. Huhn, W. Song, D. Li, and L.L. Sharp CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
6. C.H. Ries, M.A. Cannarile, S. Hoves, Benz Jr., K. Wartha, V. Runza, F. Rey-Giraud, L.P. Pradel, F. Feuerhake, and I. Klaman Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy Cancer Cell 25 2014 846 859
7. B. von Tresckow, F. Morschhauser, V. Ribrag, M.S. Topp, C. Chien, S. Seetharam, R. Aquino, S. Kotoulek, C.J. de Boer, and A. Engert An open-label, multi-center, phase 1/2 study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma Clin Cancer Res 2015
8. M.B. Pedersen, A.V. Danielse, S.J. Hamilton-Dutoit, K. Bendix, P. Nørgaard, M.B. Møller, T. Steiniche, and F. d'Amore High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma Histopathology 65 2014 490 500
9. M. Jinushi, and Y. Komohara Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside Biochim Biophys Acta (BBA) - Reviews on Cancer 1855 2015 123 130
10. F.O. Martinez, and S. Gordon The evolution of our understanding of macrophages and translation of findings toward the clinic Expert Rev Clin Immunol 11 2015 5 13
11. R. Noy, and J.W. Pollard Tumor-associated macrophages: from mechanisms to therapy Immunity 41 2014 49 61
12. P.A. Cassier, C.A. Gomez-Roca, A. Italiano, M. Cannarile, C. Ries, A. Brillouet, C. Mueller, G. Meneses-Lorente, M. Baehner, and J. Ratnayake Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS) ASCO Meeting Abstracts 32 2014 10504
13. E. Hatzimichael, G. Georgiou, L. Benetatos, and E. Briasoulis Gene mutations and molecularly targeted therapies in acute myeloid leukemia Am J Blood Res 3 2013 29 51
14. P.P. Patwardhan, O. Surriga, M.J. Beckman, E. de Stanchina, R.P. Dematteo, W.D. Tap, and G.K. Schwartz Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs Clin Cancer Res 20 2014 3146 3158
15. W.D. Tap, S.P. Anthony, B. Chmielowski, A.P. Staddon, A.L. Cohn, G. Shapiro, I. Puzanov, E.L. Kwak, A.J. Wagner, and C. Peterfy A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS) ASCO Meeting Abstracts 32 2014 10503
16. S.P. Anthony, I. Puzanov, P.S. Lin, K.B. Nolop, B. West, and D.D. Von Hoff Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit ASCO Meeting Abstracts 29 2011 3093
17. N.A. Butowski, H. Colman, J.F. De Groot, A.M.P. Omuro, L. Nayak, T.F. Cloughesy, A. Marimuthu, A. Perry, J.J. Phillips, and B. West A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma ASCO Meeting Abstracts 32 2014 2023
18. C.H. Moskowitz, A. Younes, S. de Vos, R.G. Bociek, L.I. Gordon, T.E. Witzig, R.D. Gascoyne, B. West, K. Nolop, and C. Steidl CSF1R inhibition by PLX3397 in patients with relapsed or refractory hodgkin lymphoma: results from a phase 2 single agent clinical trial ASH Annual Meeting Abstracts 120 2012 1638 1640
19. A. Sica, P. Invernizzi, and A. Mantovani Macrophage plasticity and polarization in liver homeostasis and pathology Hepatology 59 2014 2034 2042
20. Z.A. Radi, P.H. Koza-Taylor, R.R. Bell, L.A. Obert, H.A. Runnels, J.S. Beebe, M.P. Lawton, and S. Sadis Increased serum enzyme levels associated with Kupffer cell reduction with no signs of hepatic or skeletal muscle injury Am J Pathol 179 2011 240 247
21. P.J. Murray, J.E. Allen, S.K. Biswas, E.A. Fisher, D.W. Gilroy, S. Goerdt, S. Gordon, J.A. Hamilton, L.B. Ivashkiv, and T. Lawrence Macrophage activation and polarization: nomenclature and experimental guidelines Immunity 41 2014 14 20
22. M.J. Cavnar, S. Zeng, T.S. Kim, E.C. Sorenson, L.M. Ocuin, V.P. Balachandran, A.M. Seifert, J.B. Greer, R. Popow, and M.H. Crawley KIT oncogene inhibition drives intratumoral macrophage M2 polarization J Exp Med 210 2013 2873 2886
23. M. Chittezhath, M.K. Dhillon, J.Y. Lim, D. Laoui, I.N. Shalova, Y.L. Teo, J. Chen, R. Kamaraj, L. Raman, and J. Lum Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression Immunity 41 2014 815 829
24. F.O. Martinez, L. Helming, R. Milde, A. Varin, B.N. Melgert, C. Draijer, B. Thomas, M. Fabbri, A. Crawshaw, and L.P. Ho Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences Blood 121 2013 e57 e69
25. D. Hashimoto, A. Chow, C. Noizat, P. Teo, M.B. Beasley, M. Leboeuf, C.D. Becker, P. See, J. Price, and D. Lucas Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes Immunity 38 2013 792 804
26. R.A. Franklin, W. Liao, A. Sarkar, M.V. Kim, M.R. Bivona, K. Liu, E.G. Pamer, and M.O. Li The cellular and molecular origin of tumor-associated macrophages Science 344 2014 921 925
27. C.I. Caescu, X. Guo, L. Tesfa, T.D. Bhagat, A. Verma, D. Zheng, and E.R. Stanley Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21 Blood 2015
28. L. Squadrito Mario, F. Pucci, L. Magri, D. Moi, D. Gilfillan Gregor, A. Ranghetti, A. Casazza, M. Mazzone, R. Lyle, and L. Naldini miR-511-3p modulates genetic programs of tumor-associated macrophages Cell Reports 1 2012 141 154
29. J. Xue, S.V. Schmidt, J. Sander, A. Draffehn, W. Krebs, I. Quester, D. De Nardo, T.D. Gohel, M. Emde, and L. Schmidleithner Transcriptome-based network analysis reveals a spectrum model of human macrophage activation Immunity 40 2014 274 288
30. J.G. Conway, B. McDonald, J. Parham, B. Keith, D.W. Rusnak, E. Shaw, M. Jansen, P. Lin, A. Payne, and R.M. Crosby Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580 Proceedings of the National Academy of Sciences of the United States of America 102 2005 16078 16083
31. D.G. DeNardo, D.J. Brennan, E. Rexhepaj, B. Ruffell, S.L. Shiao, S.F. Madden, W.M. Gallagher, N. Wadhwani, S.D. Keil, and S.A. Junaid Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy Cancer Discovery 1 2011 54 67
32. H. Ohno, K. Kubo, H. Murooka, Y. Kobayashi, T. Nishitoba, M. Shibuya, T. Yoneda, and T. Isoe A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model Mol Cancer Therapeut 5 2006 2634 2643
33. S.M. Pyonteck, L. Akkari, A.J. Schuhmacher, R.L. Bowman, L. Sevenich, D.F. Quail, O.C. Olson, M.L. Quick, J.T. Huse, and V. Teijeiro CSF-1R inhibition alters macrophage polarization and blocks glioma progression Nat Med 19 2013 1264 1272
34. C.J. Burns, M.F. Harte, X. Bu, E. Fantino, M. Giarrusso, M. Joffe, M. Kurek, F.S. Legge, P. Razzino, and S. Su Discovery of 2-(α-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS Bioorg Med Chem Lett 19 2009 1206 1209
35. B.L. Lokeshwar, and H.S. Lin Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor J Immunol 141 1988 483 488
36. T. Sudo, S. Nishikawa, M. Ogawa, H. Kataoka, N. Ohno, A. Izawa, S.-I. Hayashi, and S.-I. Nishikawa Functional hierarchy of c-kit ans c-fms in intramarrow production of CFU-M Oncogene 11 1995 2469-2276
37. K.P.A. MacDonald, J.S. Palmer, S. Cronau, E. Seppanen, S. Olver, N.C. Raffelt, R. Kuns, A.R. Pettit, A. Clouston, and B. Wainwright An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation Blood 116 2010 3955 3963
38. B. Ruffell, D. Chang-Strachan, V. Chan, A. Rosenbusch, C.M.T. Ho, N. Pryer, D. Daniel, E.S. Hwang, H.S. Rugo, and L.M. Coussens Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells Cancer Cell 26 2014 623 637
39. J.B. Mitchem, D.J. Brennan, B.L. Knolhoff, B.A. Belt, Y. Zhu, D.E. Sanford, L. Belaygorod, D. Carpenter, L. Collins, and D. Piwnica-Worms Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses Cancer Res 73 2013 1128 1141
40. J. Xu, J. Escamilla, S. Mok, J. David, S. Priceman, B. West, G. Bollag, W. McBride, and L. Wu CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer Cancer Res 73 2013 2782 2794
41. M. De Palma, M.A. Venneri, C. Roca, and L. Naldini Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells Nat Med 9 2003 789 795
42. S.J. Priceman, J.L. Sung, Z. Shaposhnik, J.B. Burton, A.X. Torres-Collado, D.L. Moughon, M. Johnson, A.J. Lusis, D.A. Cohen, and M.L. Iruela-Arispe Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy Blood 115 2010 1461 1471
43. Y. Kubota, K. Takubo, T. Shimizu, H. Ohno, K. Kishi, M. Shibuya, H. Saya, and T. Suda M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis J Exp Med 206 2009 1089 1102
44. M.A. Forget, J.L. Voorhees, S.L. Cole, D. Dakhlallah, I.L. Patterson, A.C. Gross, L. Moldovan, X. Mo, R. Evans, and C.B. Marsh Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer PLoS One 9 2014 e98623
45. D.S. Chen, and I. Mellman Oncology meets immunology: the cancer-immunity cycle Immunity 39 2013 1 10
46. D.B. Page, M.A. Postow, M.K. Callahan, J.P. Allison, and J.D. Wolchok Immune modulation in cancer with antibodies Annu Rev Med 65 2014 185 202
47. P. Allavena, and A. Mantovani Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment Clin Exp Immunol 167 2012 195 205
48. T.S. Johnson, and D.H. Munn Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance Immunol Invest 41 2012 765 797
49. P.C. Rodriguez, D.G. Quiceno, and A.C. Ochoa l-Arginine availability regulates T-lymphocyte cell-cycle progression Blood 109 2007 1568 1573
50. S. Mok, R.C. Koya, C. Tsui, J. Xu, Robert Ld, L. Wu, T.G. Graeber, B.L. West, G. Bollag, and A. Ribas Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy Cancer Res 74 2014 153 161
51. M. Sluijter, T.C. van der Sluis, P.A. van der Velden, M. Versluis, B.L. West, S.H. van der Burg, and T. van Hall Inhibition of CSF-1R supports T-cell mediated melanoma therapy PLoS One 9 2014 e104230
52. Y. Zhu, B.L. Knolhoff, M.A. Meyer, T.M. Nywening, B.L. West, J. Luo, A. Wang-Gillam, S.P. Goedegebuure, D.C. Linehan, and D.G. DeNardo CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models Cancer Res 74 2014 5057 5069
53. H. Liu, C. Leo, X. Chen, B.R. Wong, L.T. Williams, H. Lin, and X. He The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1 Biochim Biophys Acta (BBA) - Proteins and Proteomics 1824 2012 938 945
54. N. Sharma, R. Wesolowski, L. Reebel, M.B. Rodal, A. Peck, B. West, D.A. Karlin, A. Dowlati, M.H. Le, and L.M. Coussens A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors ASCO Meeting Abstracts 32 2014 TPS3127
55. M.I. El-Gamal, H.S. Anbar, Y.K. Ho, and O. Chang-HHyun FMS kinase inhibitors: current status and future prospects Med Res Rev 33 2013 599 636